RxDoctor Payments Data

Geoffrey Neuner, MD

Radiation Oncology · Baltimore, MDNPI 1548464001

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $910 and has fallen 56.8% since, to $393 in 2025.

$2,337in general payments, 2019–2025

Across 65 payments — averaging $35.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$529
  • Bayer$301
  • Progenics Pharmaceuticals, Inc.$255
  • Teleflex LLC$187
  • Sumitomo Pharma America, Inc.$164
  • Immunitybio, Inc.$135
  • plus $766 from 17 others
$17,965in research payments, 2019–2025

Across 4 payments — averaging $4491.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Elekta, Inc.$10K
  • Icad, Inc$8K

What the payments were for

  • Food & beverage$2,337100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,337 in reported general payments places this provider in the 70th percentile of 108 radiation oncology providers in Maryland.

See all radiation oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$1,166,144
Medicare patients
605
Services billed
7,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl108$1,094
Alfuzosin Hcl ErAlfuzosin Hcl11$490
Oxybutynin Chloride ErOxybutynin Chloride14$451
Lidocaine Hcl ViscousLidocaine Hcl12$226
Finasteride20$132

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →